Cargando…

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis

Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Rui, Yan, Binyuan, Li, Hao, Ding, Donglin, Wang, Liguo, Pang, Jun, Ye, Dingwei, Huang, Haojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543964/
https://www.ncbi.nlm.nih.gov/pubmed/37527336
http://dx.doi.org/10.1158/0008-5472.CAN-23-0285
_version_ 1785114398798381056
author Sun, Rui
Yan, Binyuan
Li, Hao
Ding, Donglin
Wang, Liguo
Pang, Jun
Ye, Dingwei
Huang, Haojie
author_facet Sun, Rui
Yan, Binyuan
Li, Hao
Ding, Donglin
Wang, Liguo
Pang, Jun
Ye, Dingwei
Huang, Haojie
author_sort Sun, Rui
collection PubMed
description Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to improve patient outcomes. Here we demonstrated that acute treatment with the antiandrogen enzalutamide (ENZ) decreased glutathione (GSH) production, increased lipid peroxidation, and induced ferroptosis in prostate cancer cells. Consistently, meta-analysis of transcriptomic data linked the androgen-AR axis to metabolism-related biological processes, including lipid metabolism. The cystine transporter gene SLC7A11 was a key AR target, and full-length AR (AR-FL) transactivated SLC7A11 transcription by directly occupying the SLC7A11 promoter and putative enhancer regions. AR variants (AR-V) preferentially bound the SLC7A11 enhancer and upregulated SLC7A11 expression, thereby conferring resistance to ferroptosis induced by ENZ treatment. However, this effect was abolished following downregulation of AR-Vs using the dual CBP/p300 and BET inhibitor NEO2734. These findings reveal ferroptosis induction as an anticancer mechanism of antiandrogens and SLC7A11 as a direct target gene of AR-FL and AR-Vs. AR-V-mediated SLC7A11 expression represents a mechanism coupling ferroptosis resistance to prostate cancer progression. SIGNIFICANCE: Upregulation of SLC7A11 can be induced by androgen receptor variants to inhibit antiandrogen-induced prostate cancer cell ferroptosis and to drive castration resistance in prostate cancer.
format Online
Article
Text
id pubmed-10543964
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-105439642023-10-03 Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis Sun, Rui Yan, Binyuan Li, Hao Ding, Donglin Wang, Liguo Pang, Jun Ye, Dingwei Huang, Haojie Cancer Res Cancer Biology Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to improve patient outcomes. Here we demonstrated that acute treatment with the antiandrogen enzalutamide (ENZ) decreased glutathione (GSH) production, increased lipid peroxidation, and induced ferroptosis in prostate cancer cells. Consistently, meta-analysis of transcriptomic data linked the androgen-AR axis to metabolism-related biological processes, including lipid metabolism. The cystine transporter gene SLC7A11 was a key AR target, and full-length AR (AR-FL) transactivated SLC7A11 transcription by directly occupying the SLC7A11 promoter and putative enhancer regions. AR variants (AR-V) preferentially bound the SLC7A11 enhancer and upregulated SLC7A11 expression, thereby conferring resistance to ferroptosis induced by ENZ treatment. However, this effect was abolished following downregulation of AR-Vs using the dual CBP/p300 and BET inhibitor NEO2734. These findings reveal ferroptosis induction as an anticancer mechanism of antiandrogens and SLC7A11 as a direct target gene of AR-FL and AR-Vs. AR-V-mediated SLC7A11 expression represents a mechanism coupling ferroptosis resistance to prostate cancer progression. SIGNIFICANCE: Upregulation of SLC7A11 can be induced by androgen receptor variants to inhibit antiandrogen-induced prostate cancer cell ferroptosis and to drive castration resistance in prostate cancer. American Association for Cancer Research 2023-10-02 2023-08-01 /pmc/articles/PMC10543964/ /pubmed/37527336 http://dx.doi.org/10.1158/0008-5472.CAN-23-0285 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Cancer Biology
Sun, Rui
Yan, Binyuan
Li, Hao
Ding, Donglin
Wang, Liguo
Pang, Jun
Ye, Dingwei
Huang, Haojie
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title_full Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title_fullStr Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title_full_unstemmed Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title_short Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
title_sort androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543964/
https://www.ncbi.nlm.nih.gov/pubmed/37527336
http://dx.doi.org/10.1158/0008-5472.CAN-23-0285
work_keys_str_mv AT sunrui androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT yanbinyuan androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT lihao androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT dingdonglin androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT wangliguo androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT pangjun androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT yedingwei androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis
AT huanghaojie androgenreceptorvariantsconfercastrationresistanceinprostatecancerbycounteractingantiandrogeninducedferroptosis